Serum NFL concentration correlated with the estimated years to symptom onset and disease severity in autosomal dominant AD mutation carriers, suggesting its possible role as a risk biomarker in subjects with autosomal genetic mutations for AD (Table 3) [227]. This evidence concerns the gene NEFL and Alzheimer disease.